A Translational Neuroscience & Computational Evaluation of a D1R Partial Agonist for Schizophrenia (TRANSCENDS): Rationale and Study Design of a Brain-Based Clinical Trial.
Fonteneau C, Tamayo Z, Price A, Pan L, Afriyie-Agyemang Y, Agrawal S, Butler A, Cail C, Calkins M, Chakilam S, Forselius-Bielen K, Fram G, Frazier A, Gil R, Govil P, Gray DL, Grinband J, Gur RC, Haubold NK, Heffernan Z, Kegeles L, Kohler C, Lin C, Lu J, Mayer M, Pham P, Perlman G, Rahmati M, Ranganathan M, Santamauro NP, Schutte CT, Selloni A, Van Snellenberg J, Surti T, Wolf DH, Zharyy C; TRANSCENDS Group; Abi-Dargham A, Gur RE, Lieberman JA, Kantrowitz JT, Anticevic A, Cho YT, Krystal JH.
Fonteneau C, et al. Among authors: surti t.
medRxiv [Preprint]. 2025 Apr 20:2025.04.18.25326082. doi: 10.1101/2025.04.18.25326082.
medRxiv. 2025.
PMID: 40321245
Free PMC article.
Preprint.